Top

Published in:

01-06-2014 | Review

How long should we treat?

Authors: C. Roux, K. Briot

Published in: Osteoporosis International | Issue 6/2014

Abstract

Osteoporosis is a chronic disease, for which effective drugs are available. These drugs have reduced the risk of osteoporosis-related fractures in robust trials of 3–5 years duration. There is no evidence of anti-fracture efficacy for treatments of longer duration. The consequences of stopping treatments are very different for the different molecules. Bisphosphonates can be safely discontinued after 3–5 years of treatment if there was optimal adherence and if patients are no longer osteoporotic. This discontinuation cannot be applied in patients with recent fractures or for other treatments. Safety of prolonged treatment is a huge concern which must be managed appropriately. The decision of a prolonged treatment is driven by the underlying risk of fracture. This risk must be assessed regularly in order to share with the patient the benefit-risk ratio of prolonged treatment.

Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRef

Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR (1999) Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Inter Med 159:1215–1220CrossRef

Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882PubMedCrossRef

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561PubMedCrossRef

Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42PubMedCrossRef

Melton III LJ et al (2013) Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos Int 24:1689–1696

Prieto-Alhambra D, Avilèse FF, Judge A, Van Staa T, Noguès X, Arden NK et al (2012) Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality. Osteoporos Int 23:2797–2803PubMedCrossRef

Clinton J, Franta A, Polissar NL, Neradilek B, Mounce D, Fink HA et al (2009) Proximal humeral fracture as a risk factor for subsequent hip fratures. J Bone Joint Sur Am 91:503–511CrossRef

Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res 27:645–653PubMedCrossRef

10.

Vaupel JW (2010) Biodemography of human ageing. Nature 464:536–542PubMedCentralPubMedCrossRef

11.

Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP (2008) Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 67:1736–1738PubMedCentralPubMedCrossRef

12.

Leblanc ES, Hillier TA, Pedula KL, Rizzo JH, Cawthon PM, Fink HA et al (2011) Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med 171:1831–1837PubMedCentralPubMedCrossRef

13.

Karlson MK, Magnusson H, Von Shewelov T, Rosengren BE (2013) Prevention of falls in the elderly—a review. Osteoporos Int 24:747–762CrossRef

14.

Tseng VL, Yu F, Lum F, Coleman AL (2012) Risk of fractures following cataract surgery in Medicare beneficiaries. JAMA 308:493–501PubMedCrossRef

15.

Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML et al (2008) Effects of long-term strontium ranelate treatment on the risk of non vertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum 58:1687–1695PubMedCrossRef

16.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352PubMedCrossRef

17.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

18.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef

19.

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617PubMedCrossRef

20.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A et al (2005) Skeletal effects of raloxifene after 8 years: results form the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514–1524PubMedCrossRef

21.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D et al (2012) Maintenance of anti-fracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23:1115–1122PubMedCentralPubMedCrossRef

22.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef

23.

Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnston TD, Chines AA (2004) Seven years of treatement with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468PubMedCrossRef

24.

Pazianas M, Abrahamsen B, Wang Y, Russell RG (2012) Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos Int 23:2873–2884PubMedCrossRef

25.

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:240–242CrossRef

26.

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701PubMedCentralPubMedCrossRef

27.

Greenspan SL, Emkey RD, Bone HG III et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875–883PubMedCrossRef

28.

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045PubMedCrossRef

29.

Neele SJ, Evertz R, De Valk-De RG, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatement in healthy post menopausal women. Bone 30:599–603PubMedCrossRef

30.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with ow bone mass. J Clin Endocrinol Metab 96:972–980PubMedCrossRef

31.

Brown JP et al (2012) Discontinuation of denosumab and associated fracture incidence: analysis from the FREEDOM trial. J Bone Miner Res 746–752

32.

Watts NB, Chines A, Olszynski P, Mc Keever CD, Mc Clung MR, Zhou X et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372PubMedCrossRef

33.

Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L et al (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25:976–982PubMedCrossRef

34.

Cosman F, Caulin F, Eastell R, Boos N, Palermo L, Reid KR et al (2011) Who is at highest risk for new vertebral fractures after 3 years of annual zoledronic acid and who should remain on treatment? (internet). J Bone Miner Res; 26(suppl 1):Abstract 1248 cited 2012 Feb 12)

35.

Siris EE, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE et al (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27–35PubMedCentralPubMedCrossRef

36.

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus stomach, and colorectum: case–control analysis within a UK primary care cohort. BMJ 341:1–8CrossRef

37.

Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663PubMedCentralPubMedCrossRef

38.

Abrahamsen B, Pazianas M, Eiken P, Graham R, Russel G, Eastell R (2012) Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 27:679–686PubMedCrossRef

39.

Andrici J, Tio M, Eslick GD (2012) Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Aliment Pharmacol Ther 36:708–716PubMedCrossRef

40.

Sun K et al (2013) Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int 24:279–286

41.

Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Graham R, Russell G (2012) Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate – Danish national register based cohord study. Osteoporos Int 23:2693–2701PubMedCrossRef

42.

Felsenberg D, Hoffmeister B, Amling M (2006) Bisphosphonattherapie assoziierte. Kiefernedrosen Deutsches Arzteblatt 46:A3078–A3080

43.

Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF (2009) Oral bisphophonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140:61–66PubMedCrossRef

44.

Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef

45.

Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatement of osteoporosis. Recommendations from the American Dental Association Council on Scientific Affairs. November 2011 (www.ada.org)

46.

Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253PubMedCrossRef

47.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al (2012) Atypical subtrochanteric and diaphyseal femoral fractures: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294CrossRef

48.

Beaudouin-Bazire Cet al (2013) Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine 80:201–205

49.

Meier RPH, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930–936PubMedCrossRef

50.

Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef

51.

Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of 3 or 6 years of denosumab exposure in women with postmenopausal osteoporosis: result from the FREEDOM extension. Submitted

52.

Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544–2550PubMedCrossRef

53.

Schneider JP, Hinshaw WB, Su C, Solow P (2012) Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab 97:4324–4328PubMedCrossRef

54.

Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR (2013) Compound risk of high mortality following osteoporotic fracture and re-fracture in elderly women and men. J Bone Miner Res 28:2317-2324

55.

van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fracture. Ann Rheum Dis 68:99–102PubMedCrossRef

56.

Schousboe JT, Fink HA, Lui LY, Taylor BC, Ensrud KE (2006) Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture. J Bone Miner Res 21:1557–1564PubMedCrossRef

57.

Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM et al (2012) Relationship of changes in total hip bone mineral density to vertebral and non vertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 1627–1634

58.

Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and non vertebral fractures. J Bone Miner Res 27:687–693PubMedCentralPubMedCrossRef

59.

Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251–2258PubMedCrossRef

60.

Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis. Where do we go from here? N Engl J Med 366:2048–2051PubMedCrossRef

61.

Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis – for whom and for how long? N Engl J Med 366:2051–2053PubMedCentralPubMedCrossRef

62.

Seeman E (2009) To stop or not to stop, that is the question. Osteoporos Int 20:187–195PubMedCrossRef

Title: How long should we treat?
Authors: C. Roux
K. Briot
Publication date: 01-06-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 6/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-013-2433-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

How long should we treat?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study

Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation

Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers

Accuracy of spinal curvature assessed by a computer-assisted device and anthropometric indicators in discriminating vertebral fractures among individuals with back pain

Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin

Effects of 18-month low-magnitude high-frequency vibration on fall rate and fracture risks in 710 community elderly—a cluster-randomized controlled trial